UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area
code:
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On August 12, 2026, Zapata Quantum, Inc. (the “Company”) issued a press release announcing a partnership with QuEra, a copy of which is furnished herewith as Exhibit 99.1 of this Current Report on Form 8-K.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Incorporated by Reference | Filed or Furnished | |||||||||
| Exhibit # | Exhibit Description | Form | Date | Number | Herewith | |||||
| 99.1 | Furnished | |||||||||
| 104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101) | |||||||||
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 12, 2026
| ZAPATA QUANTUM, INC. | ||
| By: | /s/ Sumit Kapur | |
| Sumit Kapur, Chief Executive Officer | ||
| 3 |
Exhibit 99.1
Zapata Quantum Partners with QuEra to Advance the Commercial Viability of Quantum Applications
The partnership combines QuEra's fault-tolerant hardware roadmap with Zapata's application intelligence expertise to bridge the quantum applications gap
BOSTON, Massachusetts – August 12, 2026 – Zapata Quantum (OTCQB: ZPTA) (“Zapata,” “Zapata Quantum” or the “Company”), a leader in quantum computing algorithm and application development, today announced a partnership with QuEra, a leader in neutral-atom quantum computing, aimed at closing the quantum applications gap.
"QuEra's commitment to delivering a megaquop-class system via AWS in 2028 is exciting for the field and something we’re looking forward to supporting from the application side," said Sumit Kapur, CEO of Zapata Quantum. "We are uniquely positioned as a hardware-agnostic partner to help enterprises identify which quantum use cases matter, assess when they will become viable, and develop the applications and algorithms needed to drive transformational business value as these systems come online."
The partnership seeks to fulfill QuEra's goal of helping enterprises, government programs and HPC centers collaborate on designing and validating applications before quantum hardware reaches full fault-tolerance, and is part of the QuEra Quantum Alliance Program.
“By pairing QuEra's leadership in fault-tolerant quantum computing with Zapata's focus on application development, we can further accelerate the path from quantum capability to commercial value," said Yuval Boger, Chief Commercial Officer at QuEra Computing.
The collaboration also reflects Zapata’s broader strategy of working with technology leaders across the quantum and AI ecosystems, including its recently announced ongoing partnership with NVIDIA to apply agentic AI to accelerate quantum algorithm development.
For more information about how Zapata is delivering Quantum Application Intelligence™, please visit the Company's website.
About QuEra
QuEra is putting quantum to work. As the scientific and commercial leader in neutral-atom quantum computing, we help enterprise innovators leverage quantum to gain competitive advantage, support HPC centers as their users tackle classically intractable problems, and enable government programs to build national and sovereign capabilities. We do this by combining our quantum systems, available on-premises and via the cloud, with application co-design and collaborative research. Born at Harvard and MIT and still advancing together, QuEra builds neutral-atom systems on a public, peer-reviewed path to fault tolerance, and operates globally from Boston, New Mexico, Tokyo, Zurich, and the United Kingdom. As quantum computing moves from "one day" to "Day One," QuEra delivers practical impact today while leading the path toward large-scale, fault-tolerant systems. See what's possible at www.quera.com.
Media Contact: [email protected]
| 1 |
About Zapata Quantum
Zapata Quantum is a leading hardware-agnostic, pure-play quantum software company focused on accelerating quantum application development. With a portfolio of more than 60 granted and pending patents developed over seven years, Zapata supports applications across cryptography, pharmaceuticals, finance, materials discovery, defense, and more. The Company is the only organization to have participated across all technical areas of DARPA’s Quantum Benchmarking program and has worked with Fortune 500 enterprises and government agencies to translate quantum advances into real-world impact. The Company’s study demonstrating the potential of quantum-enabled drug discovery was recognized as one of Nature Biotechnology’s Top 10 Papers of 2025. Learn more at zapataquantum.com.
Media Contact
Taylor White
Investor Relations Contact
Richard Land
| 2 |